Hansoh Pharmaceutical Group Company Limited

SEHK:3692 Stock Report

Market Cap: HK$108.0b

Hansoh Pharmaceutical Group Balance Sheet Health

Financial Health criteria checks 5/6

Hansoh Pharmaceutical Group has a total shareholder equity of CN¥27.9B and total debt of CN¥40.3M, which brings its debt-to-equity ratio to 0.1%. Its total assets and total liabilities are CN¥31.7B and CN¥3.8B respectively. Hansoh Pharmaceutical Group's EBIT is CN¥4.2B making its interest coverage ratio -4.1. It has cash and short-term investments of CN¥23.5B.

Key information

0.1%

Debt to equity ratio

CN¥40.26m

Debt

Interest coverage ratio-4.1x
CashCN¥23.50b
EquityCN¥27.90b
Total liabilitiesCN¥3.77b
Total assetsCN¥31.67b

Recent financial health updates

Recent updates

Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Intrinsic Value Is Potentially 41% Above Its Share Price

Dec 10
Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Intrinsic Value Is Potentially 41% Above Its Share Price

Hansoh Pharmaceutical Group (HKG:3692) Seems To Use Debt Rather Sparingly

Nov 21
Hansoh Pharmaceutical Group (HKG:3692) Seems To Use Debt Rather Sparingly

Is Now The Time To Put Hansoh Pharmaceutical Group (HKG:3692) On Your Watchlist?

Nov 04
Is Now The Time To Put Hansoh Pharmaceutical Group (HKG:3692) On Your Watchlist?

Estimating The Fair Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Aug 28
Estimating The Fair Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Pinning Down Hansoh Pharmaceutical Group Company Limited's (HKG:3692) P/E Is Difficult Right Now

Aug 07
Pinning Down Hansoh Pharmaceutical Group Company Limited's (HKG:3692) P/E Is Difficult Right Now

If EPS Growth Is Important To You, Hansoh Pharmaceutical Group (HKG:3692) Presents An Opportunity

Jul 16
If EPS Growth Is Important To You, Hansoh Pharmaceutical Group (HKG:3692) Presents An Opportunity

Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt

Jun 24
Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt

Hansoh Pharmaceutical Group Company Limited's (HKG:3692) CEO Will Probably Find It Hard To See A Huge Raise This Year

Jun 06
Hansoh Pharmaceutical Group Company Limited's (HKG:3692) CEO Will Probably Find It Hard To See A Huge Raise This Year

Estimating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

May 23
Estimating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Hansoh Pharmaceutical Group Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

May 01
Hansoh Pharmaceutical Group Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Do Hansoh Pharmaceutical Group's (HKG:3692) Earnings Warrant Your Attention?

Mar 28
Do Hansoh Pharmaceutical Group's (HKG:3692) Earnings Warrant Your Attention?

There's Reason For Concern Over Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Massive 28% Price Jump

Mar 04
There's Reason For Concern Over Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Massive 28% Price Jump

An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 28% Undervalued

Feb 16
An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 28% Undervalued

Financial Position Analysis

Short Term Liabilities: 3692's short term assets (CN¥27.4B) exceed its short term liabilities (CN¥3.4B).

Long Term Liabilities: 3692's short term assets (CN¥27.4B) exceed its long term liabilities (CN¥336.6M).


Debt to Equity History and Analysis

Debt Level: 3692 has more cash than its total debt.

Reducing Debt: 3692's debt to equity ratio has increased from 0% to 0.1% over the past 5 years.

Debt Coverage: 3692's debt is well covered by operating cash flow (11558%).

Interest Coverage: 3692 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 15:06
End of Day Share Price 2024/12/24 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hansoh Pharmaceutical Group Company Limited is covered by 32 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sharon ShiBOCI Research Ltd.
Bo LiBofA Global Research
Jin ZhangChina International Capital Corporation Limited